Clichy

• A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Pati … Not authorised
  2022-502043-35-00 5 Advanced Biliary Tract Cancers
• Baricitinib for treating hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international phase II … Not authorised
  2023-503480-42-00 10 Hospital-acquired pneumonia
• TIC-TAC-SAM « Comparison of two strategies of etoposide initiation in severe sporadic hemophagocytic lymphohistiocytosis in intensive care: … Not authorised
  2024-511807-41-00 5 Hemophagocytic lymphohistiocytosis (HLH)
• Evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendoc … Not authorised
  2024-515603-19-00 4 Localized digestive Neuroendocrine Carcinomas
• PRODIGE 113 (FFCD 2314) – REWENEC – 01 STUDY Randomized trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI with a hybrid synthetic co … Not authorised
  2024-519922-19-00 4 Neuroendocrine carcinoma of gastro-enteropancreatic or unknown origin
• A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown
  2025-523766-25-00 5 Ulcerative colitis
• Impact of low dose epinephrine in the management of out-of-hospital cardiac arrest on neurological outcome: A multicenter randomized and do … Pending
  2023-505349-26-00 5 Out-of-hospital cardiac arrest.
• TIC-TAC-SAM « Comparison of two strategies of etoposide initiation in severe sporadic hemophagocytic lymphohistiocytosis in intensive care: … Pending
  2024-511807-41-01 5 Hemophagocytic lymphohistiocytosis (HLH)
• CANDISHORT : A randomized study of a short duration therapy for candidemia Pending
  2024-514244-81-00 5 Uncomplicated candidemia
• Comparison of azathioprine to methotrexate in combination therapy with adalimumab in Crohn’s Disease: an open-label randomized controlled tr … Pending
  2024-514633-38-00 5 Crohn’s Disease
• FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial Pending
  2024-514964-24-00 5 ulcerative colitis
• Evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendoc … Pending
  2024-515603-19-01 4 Localized digestive Neuroendocrine Carcinomas
• Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol Pending
  2024-516232-10-00 6 Serious infections in critically ill patients treated with antibiotics
• BICCS - Beta-lactam Intermittent versus Continuous infusion and Combination antibiotic therapy in Sepsis Pending
  2024-516849-39-01 5 antibiotic therapy in Sepsis
• Bosentan in the treatment of Giant Cell Arteritis Pending
  2024-517030-17-00 4 Newly diagnosed or relapsing Giant-cell arteritis
• Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Duct … Pending
  2024-518139-12-00 4 locally advanced or metastatic Pancreatic ductal adenocarcinoma
• REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis. Pending
  2024-519298-21-00 5 Cancer-Associated Thrombosis (CAT).
• PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients … Pending
  2024-519753-11-00 4 Resectable borderline pancreatic adenocarcinoma
• Optimal Duration of Antibiotic Therapy in Drained Pyogenic Liver Abscess: 3 weeks versus 6 weeks, a non-inferiority trial Pending
  2025-520940-14-00 6 Pyogenic liver abscess
• PREP-ANCA - Comparison of a strategy based on clinic-biological surveillance versus pre-emptive treatment with rituximab in the event of ANC … Pending
  2025-522049-23-00 6 granulomatosis with polyangiitis and microscopic polyangiitis
• First adjuvant trial in locally resected aggressive pancreatic neuroendocrine tumors: a randomized phase III investigating the efficacy of s … Pending
  2025-523593-16-00 5 Pancreatic NeuroEndocrine Tumors (PanNET) ; Aggressive stage I-III wel
• A clinical study to investigate the safety and tolerability of efimosfermin alfa injection in participants with known or suspected F2- or F3 … Pending
  2025-523674-16-00 5 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• A pivotal clinical study to investigate the safety and efficacy of efimosfermin alfa injection in participants with biopsyconfirmed F2- or F … Pending
  2025-523675-39-00 5 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta … Pending
  2025-523869-22-00 5 advanced or metastatic extrapulmonary neuroendocrine carcinoma

Showing 1–24 of 182 trials